硅胶假体乳房增大成形术后硅胶淋巴结病
该回顾性观察性横断面研究纳入2011至2021年以色列Shamir Assaf Harofeh医疗中心614名女性(1209侧乳房),术前超声将患者分为有或无硅胶瘤组。硅胶瘤发生率为13.6%(165侧乳房);多因素分析显示假体破裂(OR=6.342)、Mentor假体(OR=3.047)和PIP假体(OR=3.475)为独立危险因素,严重包膜挛缩亦相关(OR=1.65)。作者认为应告知候选人硅胶迁移风险,对高危患者加强腋窝监测,可考虑预防性置换或取出假体。
要点
- 硅胶瘤发生率为13.6%(165侧乳房),共纳入614名女性(1209侧乳房)。
- 假体破裂(OR=6.342)、Mentor假体(OR=3.047)和PIP假体(OR=3.475)为独立危险因素。
- 严重包膜挛缩与硅胶瘤发生率高相关(OR=1.65)。
核心结论
- 硅胶假体乳房增大成形术后硅胶瘤发生率为13.6%(165侧乳房),假体破裂、Mentor和PIP假体及严重包膜挛缩与硅胶瘤发生率高相关。
- 作者认为应告知候选人硅胶迁移的潜在风险,对假体破裂、严重包膜挛缩及使用Mentor和PIP假体的患者加强腋窝监测,可考虑预防性置换或取出假体以降低硅胶瘤风险。
研究设计与样本
- 回顾性观察性横断面研究,2011至2021年在以色列Shamir Assaf Harofeh医疗中心开展,术前超声将患者分为有硅胶瘤组和无硅胶瘤组。
- 共614名女性(1209侧乳房)符合纳入标准。
主要发现
- 硅胶瘤发生率为13.6%(165侧乳房)。
- 单因素分析中,年龄较大(47岁 vs 43岁,P < .001)、假体置入时间较长(12.2年 vs 11年,P = .026)、假体破裂(59.4% vs 17.7%,P < .001)、胸肌下置入(P = .019)、严重包膜挛缩、使用Mentor假体(Irvine, CA;P = .007)和PIP假体(La Seyne-sur-Mer, France;P = .001)与硅胶瘤存在显著相关。
- 多因素分析中,假体破裂(OR=6.342)、Mentor假体(OR=3.047)和PIP假体(OR=3.475)为与硅胶瘤发生率较高相关的独立危险因素。
- 严重包膜挛缩也与硅胶瘤发生率较高相关(OR=1.65)。
临床怎么用
- 作者认为外科医生应告知候选人硅胶迁移的潜在风险。
- 作者认为对假体破裂、严重包膜挛缩及使用Mentor和PIP假体的患者,更密切监测腋窝以发现硅胶瘤是适宜的,可考虑预防性置换或取出假体以降低硅胶瘤风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Silicone implants are by far the most widely used implant globally for breast augmentation. Despite technological advancements, complications persist, with silicone lymphadenopathy (siliconoma) being a noteworthy concern. This phenomenon has been inadequately addressed in the existing literature. OBJECTIVES: The aim of this study was to characterize axillary siliconomas and identify potential risk factors to help reduce their occurrence. METHODS: The authors conducted a retrospective observational cross-sectional study spanning between 2011 and 2021 at the Shamir Assaf Harofeh Medical Center, Israel. Preoperative ultrasound examination was conducted, categorizing patients into those with siliconomas and those without. RESULTS: A total of 614 women (1209 breasts) met the inclusion criteria. The incidence of siliconomas was 13.6% (165 breasts). In univariate analysis, older age (47 years vs 43 years, P < .001), older implant age (12.2 years vs 11 years, P = .026), ruptured implants (59.4% vs 17.7%, P < .001), subpectoral placement (P = .019), severe capsular contracture, and the use of Mentor implants (Irvine, CA; P = .007) and Poly Implant Prothèse implants (PIP; La Seyne-sur-Mer, France; P = .001) correlated significantly with the presence of siliconomas. In a multivariate analysis, implant rupture (odds ratio [OR] = 6.342), and implant manufacturer-Mentor (OR = 3.047) and PIP (OR = 3.475)-were identified as independent risk factors associated with a higher incidence of siliconomas. Severe capsular contracture was also associated with a higher incidence of siliconomas (OR = 1.65). CONCLUSIONS: Surgeons should inform candidates about the potential risk of silicone migration. Patients with ruptured implants, significant capsular contracture, and Mentor and PIP implants face an increased risk for developing siliconomas. Closer monitoring for the detection of siliconomas in the axilla for these patients is advisable, and potential prophylactic replacement or removal of implants may be warranted to mitigate siliconoma risk.
引用
- Rosenthal A, Goldbart Nahmias A, Heller L, et al. Silicone Lymphadenopathy Following Augmentation Mammoplasty With Silicone Implants. Aesthet Surg J. 2024. PMID: 38762900. doi:10.1093/asj/sjae113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。